Claims for Patent: 5,846,987

Summary for Patent: 5,846,987

Title:	Retroviral protease inhibiting compounds
Abstract:	A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
Inventor(s):	Kempf; Dale J. (Libertyville, IL), Norbeck; Daniel W. (Crystal Lake, IL), Sham; Hing Leung (Gurnee, IL), Zhao; Chen (Gurnee, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	08/821,609
Patent Claims:	1. A combination pharmaceutical agent for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N- ((5-thiazolyl) methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor. 2. The combination of claim 1 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT). 3. The combination of claim 1 wherein the reverse transcriptase inhibitor is zidovudine. 4. The combination of claim 1 wherein the reverse transcriptase inhibitor is dideoxycytidine. 5. The combination of claim 1 wherein the reverse transcriptase inhibitor is dideoxyinosine. 6. The combination of claim 1 wherein the reverse transcriptase inhibitor is D4T. 7. The combination of claim 1 wherein the reverse transcriptase inhibitor is BCH-189. 8. The combination of claim 1 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino) -1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the reverse transcriptase inhibitor are each formulated as separate compositions. 9. The combination of claim 8 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at the same time. 10. The combination of claim 8 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl) -amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at different times. 11. A combination of pharmaceutical agents for the treatment of an HIV infection comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor. 12. The combination of claim 11 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT). 13. The combination of claim 11 wherein the reverse transcriptase inhibitor is zidovudine. 14. The combination of claim 11 wherein the reverse transcriptase inhibitor is dideoxycytidine. 15. The combination of claim 11 wherein the reverse transcriptase inhibitor is dideoxyinosine. 16. The combination of claim 11 wherein the reverse transcriptase inhibitor is D4T. 17. The combination of claim 11 wherein the reverse transcriptase inhibitor is BCH-189. 18. The combination of claim 11 wherein (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl) methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)- amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the reverse transcriptase inhibitor are each formulated as separate compositions. 19. The combination of claim 18 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N- Methyl-N-((2-isopropyl-4-thiazolyl) methyl)amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)- amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at the same time. 20. The combination of claim 18 wherein the formulation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino)-1,6-diphe nyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and the formulation of the reverse transcriptase inhibitor are to be administered at different times. 21. (2S,3S,5S)-5-(N- (N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)am ino)-2-(N-((5-thiazolyl) methoxycarbonyl)-amino)- 1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and a reverse transcriptase inhibitor for concomitant administration for the treatment of an HIV infection. 22. (2S,3S,5S)-5-(N-(N-((N-Methyl-N -((2-isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-t hiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and zidovudine for concomitant administration for the treatment of an HIV infection. 23. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-th iazolyl)methyl)-amino)carbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhe xane or a pharmaceutically acceptable salt thereof and dideoxycytidine for concomitant administration for the treatment of an HIV infection. 24. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)meth yl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl) methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and dideoxyinosine for concomitant administration for the treatment of an HIV infection. 25. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2 -isopropyl-4-thiazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiaz olyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and D4T for concomitant administration for the treatment of an HIV infection. 26. (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-th iazolyl)methyl)-amino)carbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycar bonyl)-amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and BCH-189 for concomitant administration for the treatment of an HIV infection. 27. A combination pharmaceutical agent for administration to a human for the treatment of an HIV infection comprising: a) a first pharmaceutical composition comprising (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and b) a second pharmaceutical composition comprising a reverse transcriptase inhibitor. 28. The combination of claim 27 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT). 29. The combination of claim 27 wherein the reverse transcriptase inhibitor is zidovudine. 30. The combination of claim 27 wherein the reverse transcriptase inhibitor is dideoxycytidine. 31. The combination of claim 27 wherein the reverse transcriptase inhibitor is dideoxyinosine. 32. The combination of claim 27 wherein the reverse transcriptase inhibitor is D4T. 33. The combination of claim 27 wherein the reverse transcriptase inhibitor is BCH-189. 34. Use of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl) amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphenyl-3-hydroxyhe xane or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for concomitant administration to a human with a reverse transcriptase inhibitor for the treatment of an HIV infection. 35. The use of claim 34 wherein the reverse transcriptase inhibitor is selected from the group consisting of dideoxycytidine (DDC), dideoxyinosine (DDI), BCH-189, AzdU, carbovir, DDA, D4C, D4T, DP-AZT, FLT (fluorothymidine), 5-halo-3'-thia-dideoxycytidine, PMEA and zidovudine (AZT). 36. The use of claim 34 wherein the reverse transcriptase inhibitor is zidovudine. 37. The use of claim 34 wherein the reverse transcriptase inhibitor is dideoxycytidine. 38. The use of claim 34 wherein the reverse transcriptase inhibitor is dideoxyinosine.